In this interview Ira Zackon, MD, highlights data on bispecific antibody use in patients with multiple myeloma in the community setting as presented at ASH 2025.
Zackon noted that the retrospective observational study included representation of Black Americans and rural populations usually left out of clinical trials, but the real-world research in multiple myeloma remains limited and further analysis will need to be completed.
“It’s certainly important that bispecific antibodies are able to be delivered in the community oncology setting in order to really expand access so patients can get